TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SEOUL, South Korea, Nov. 28, 2017 -- ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced a poster presentation on its CRISPR technology at the upcoming American Society of Hematology (ASH) Annual Meeting, being held December 9-12 in Atlanta, Georgia.
The poster presentation entitled “CRISPR/Cas9-Mediated Diacylglycerol Kinase Knockout Potentiates Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T-Cells” will cover a study that explored a potential solution to tumors evading immune surveillance by deactivating T cells. Researchers strengthened T cell function by deleting Diacylglycerol kinase (DGKs) using CRISPR/Cas9. The study found that the observed biological effects may also yield new strategies for improving the efficacy of T-cell therapy in combination with signal 2 checkpoint inhibitors in clinical applications.
Details of the presentation are below:
| Poster: | 3182 - CRISPR/Cas9-Mediated Diacylglycerol Kinase Knockout Potentiates Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T-Cells | |
| Lead Author: | In-Young Jung, MS | |
| Poster Session: | 703: Adoptive Immunotherapy: Poster II | |
| Date: | Sunday, December 10, 2017 | |
| Time: | 6:00 - 8:00pm CT | |
| Location: | Georgia World Congress Center Building A, Level 1, Hall A2 |
About ToolGen, Inc.
ToolGen, Inc. is a biotechnology company focused on the development and application of genome editing technologies. It creates and holds intellectual property rights for essential tools and technologies for editing the genetic information in microbial, plant, animal, and human cells. ToolGen’s mission is to translate the potential of its innovative platform technology into transformative products for biomedicine and agriculture. For more information, please visit www.toolgen.com.
Contacts
Company – Seokjoong Kim +82-2-873-8168
Media – Kirsten Thomas (508) 280-6592
Investors – Tram Bui (646) 536-7035
